Drug Addiction: From Basic Research to Therapy by Rao S. RapakaDrug Addiction: From Basic Research to Therapy by Rao S. Rapaka

Drug Addiction: From Basic Research to Therapy

EditorRao S. Rapaka

Paperback | November 25, 2010

Pricing and Purchase Info

$306.38 online 
$336.95 list price save 9%
Earn 1532 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

This book provides a comprehensive overview of physiological, biochemical, and genetic pathways underlying drug addiction, and resultant efforts to develop novel treatment strategies dealing with drug addiction and other CNS disorders where the neurophysiological processes overlap, such as treatment of pain. The volume focuses on the translation of fundamental addiction research to a variety of treatments and brings together scientists with wide ranging expertise.
Title:Drug Addiction: From Basic Research to TherapyFormat:PaperbackDimensions:805 pagesPublished:November 25, 2010Publisher:Springer New YorkLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1441926321

ISBN - 13:9781441926326

Look for similar items by category:

Reviews

Table of Contents

I. General Topics1. Per Svenning, Angus C. Nairn and Paul GreengardDARPP-32 mediates the actions of multiple drugs of abuse 2. Young-Won Chin, Marcy J. Balunas, Hee Byung Chai, and A. Douglas KinghornDrug discovery from natural sources3. Patricia H. ReggioComputational methods in drug design: Modeling G protein-coupled receptor monomers, dimers and oligomers4. Joni L RutterSymbiotic relationship of pharmacogenetics and drugs of abuse 5. Eric Peterson, S. Michael Owens, and Ralph L. HenryMonoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse6. MJ Kuhar, JN Jaworski, GW Hubert, KB Philpot and G. DominguezCART peptides play a role in drug abuse and potential therapeutic agents 7. Madhavan P.N. Nair, Jessica L. Reynolds, Supriya D. Mahajan, Stanley A.Schwartz, Ravikumar Aalinkeel, Bindukumar B. Don SykesRNAi directed inhibition of DC-SIGN in dendritic cells. Prospects for HIV-1 therapy8. Martin W. Adler, Ellen B. Geller, Xiaohong Chen, and Thomas J. Rogers Viewing chemokines as a third major system in the brain9. Andrea Piserchio, Mark Spaller, and Dale F. MierkeTargeting the PDZ domains of molecular scaffolds of transmembrane ion channels10. Lorise C. Gahring and Scott W. Rogers Neuronal nicotinic acetylcholine receptor expression and function on non-neuronal cellsII. Transporters & stimulants & HALLUCINOGENS1. Evan L. Riddle, Annette E. Fleckenstein and Glen R. HansonRole of monamine transporters in mediating psychostimulant effects2. F. Ivy Carroll, James L. Howard, Leonard L. Howell, Barbara S. Fox, and Michael J. Kuhar Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse3. Kellie J. White, Crystal C. Walline, and Eric L. BarkerSerotonin transporters: Implications for antidepressant drug development4. Tobin J. Dickerson and Kim D. JandaRecent advances for the treatment of cocaine abuse: Central nervous system immunopharmacotherapy5. Thomas E. Prisinzano, Kevin Tidgewell and Wayne W. HardingKappa opioids as potential treatments for stimulant dependence 6. Lankupalle D. Jayanthi and Sammanda RamamoorthyRegulation of monoamine transporters: Molecular targets of psychostimulants and therapeutic antidepressants 7. Harel WeinsteinHallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors 8. Christopher K. Surratt, Okechukwu T. Ukairo and Suneetha RamanujapuramRecognition of psychostimulants, antidepressants and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters9. Richard B. Rothman, Bruce E Blough, and Michael H BaumannDual DA/5-HT releasers as potential medications for stimulant and alcohol addictions10. Anita H. LewinReceptors of mammalian trace aminesIII. Drug Design: Nicotine, opioids and related ligands1. Jeffrey R. DeschampsThe role of crystallography in drug design2. Peter W. SchillerOpioid peptide-derived analgesics3. Subramaniam AnanthanOpioid ligands with mixed mu/delta receptor interactions: An emerging approach to novel analgesics 4. Nurulain Zaveri, Faming Jiang, Cris Olsen, Wilma Polgar and Lawrence TollSmall molecule agonists and antagonists of the opioid-receptor like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at the NOP receptor 5. Matthew D. Metcalf and Andrew CoopKappa opioid antagonists: Past successes and future prospects6. R. A. Houghten, C.T. Dooley, and J.R. AppelThe use of mixture-based combinatorial libraries in conjunction with in vitro and direct in vivo testing for the identification of highly active and specific opiate ligands7. Mark G. LeSage, Daniel E. Keyler, and Paul R. PentelCurrent status of immunologic approaches to treating tobacco dependence: Vaccines and nicotine-specific antibodies8. Victor J. Hruby, Frank Porreca, Henry I. Yamamura, Gordon Tollin, Richard S. Agnes, Yeon Sun Lee, Minying Cai, Isabel Alves, Scott Cowell, Eva Varga, Peg Davis, Zdzislaw Salamon, William Roeske, Todd Vanderah, and Josephine LaiNew paradigms and tools in drug design for pain and addictionIV. Opioids: General1. Lloyd D. FrickerNeuropeptide processing enzymes: Applications for drug discovery 1. 2. Ken A. Witt and Thomas P. DavisCNS Drug delivery: Opioid peptides and the blood-brain barrier3. Hazel H. Szeto Cell-permeable, mitochondrial-targeted, peptide antioxidants 4. Achla Gupta, Fabien M. Décaillot, and Lakshmi A. DeviTargeting opioid receptor heterodimers: Strategies for screening and drug development5. Henry I. Mosberg, Irina D. Pogozheva, Magdalena J. PrzydziaHomology modeling of opioid receptor-ligand complexes using experimental constraints6. Brian E. Kane, Bengi Svensson, David M. FergusonMolecular recognition of opioid receptor ligands7. Erica Wittwer and Steven E. Kern The role of morphine's metabolites in analgesia: concepts and controversies8. Kristen M. Raehal and Laura M. BohnMu Opioid receptor regulation and opiate responsiveness 9. Soundar Regunathan Agmatine: Possible biological role and therapeutic applications in morphine tolerence/dependence V. Cannabinoids1. Roger PertweeThe therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids2. Anu Mahadevan and R.K. RazdanFurther advances in the synthesis of endocannabinoid related ligands3. Sumner BursteinAjulemic acid (IP-751): synthesis, proof of principle, toxicity studies and clinical trials 4. Brian F. Thomas, Yanan Zhang, Marcus Brakeen, Kevin M. Page, S. Wayne Mascarella and Herbert H. Seltzman Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally-constrained analogs5. Steven R. ChildersActivation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids6. Anita Hermann, Martin Kaczocha, and Dale G. Deutsch2-Archidonoylglycerol (2-AG) membrane transport: history and outlook7. Andrea G. Hohmann and Richard L. Suplita, IIEndocannabinoid mechanisms of pain modulation

Editorial Reviews

From the reviews:"This book grew out of a symposium entitled 'Frontiers in Science: Drug Addiction-From Basic Research to Therapies' held at the end of 2004. . The book is composed of 44 chapters, all concerned with basic science research relevant to drug dependence. . even for basic scientists this book is best approached as one where at most a few chapters may be of interest to any researcher . in drug addiction." (Jason White, Drug And Alcohol Review, Vol. 28, July, 2009)